Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq analysis for MDA-MB-468 cells treated with SAHA and sonidedgib

ABSTRACT: Epigenetic therapies that cause genome-wide epigenetic alterations, could trigger local interplay between different histone marks, leading to a switch of transcriptional outcome and cellular phenotypes. In human cancers with diverse oncogenic activation, how oncogenic pathways cooperate with epigenetic modifiers to regulate the histone mark interplay is poorly understood. We herein discover that the hedgehog (Hh) pathway reprograms the histone methylation landscape in triple-negative breast cancer (TNBC), which facilitates histone acetylation caused by histone deacetylase (HDAC) inhibitors and gives rise to new therapeutic vulnerability of combination therapies. Specifically, overexpression of zinc finger protein of the cerebellum 1 (ZIC1) in TNBC promotes Hh activation, facilitating the switch of H3K27 methylation (H3K27me) to acetylation (H3K27ac). The mutually exclusive relationship of H3K27me and H3Kac allows their functional interplay at oncogenic gene locus and switches therapeutic outcomes. Using multiple in vivo TNBC models including patient-derived xenograft, we show that Hh signaling-orchestrated H3K27me and H3Kac interplay tailors combination epigenetic drugs in treating TNBC.

ORGANISM(S): Homo sapiens

PROVIDER: GSE187427 | GEO | 2024/10/18

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

H3K27ac and H3K27me3 ChIP-seq analysis for MDA-MB-468 cells treated with SAHA and sonidedgib

Project description:Epigenetic therapies that cause genome-wide epigenetic alterations, could trigger local interplay between different histone marks, leading to a switch of transcriptional outcome and cellular phenotypes. In human cancers with diverse oncogenic activation, how oncogenic pathways cooperate with epigenetic modifiers to regulate the histone mark interplay is poorly understood. We herein discover that the hedgehog (Hh) pathway reprograms the histone methylation landscape in triple-negative breast cancer (TNBC), which facilitates histone acetylation caused by histone deacetylase (HDAC) inhibitors and gives rise to new therapeutic vulnerability of combination therapies. Specifically, overexpression of zinc finger protein of the cerebellum 1 (ZIC1) in TNBC promotes Hh activation, facilitating the switch of H3K27 methylation (H3K27me) to acetylation (H3K27ac). The mutually exclusive relationship of H3K27me and H3Kac allows their functional interplay at oncogenic gene locus and switches therapeutic outcomes. Using multiple in vivo TNBC models including patient-derived xenograft, we show that Hh signaling-orchestrated H3K27me and H3Kac interplay tailors combination epigenetic drugs in treating TNBC.

2024-10-18 | GSE189215 | GEO

KAT6A acetylation of SMAD3 regulates tumor metastasis in triple-negative breast cancer

Project description:Aberrant SMAD3 activation has been implicated as a driving event in cancer metastasis. However, the drivers of SMAD3 activation are poorly defined. Here, we identify SMAD3 as a non-histone substrate of lysine acetyltransferase 6A (KAT6A). The acetylation of SMAD3 at K20 and K117 by KAT6A with promotes SMAD3 association with oncogenic H3K23ac reader TRIM24 and upregulation of immune response-related cytokines. This event in turn leads to enhanced myeloid-derived suppressor cell (MDSC) recruitment and triple-negative breast cancer (TNBC) metastasis. Inhibiting KAT6A in combination with anti-PD-L1 therapy in treating breast cancer xenograft-bearing animals markedly attenuates TNBC metastasis and provides a significant survival benefit. Thus, our work presents an KAT6A acetylation-dependent regulatory mechanism governing SMAD3 oncogenic function and provides insight into how targeting an epigenetic factor with immunotherapies enhances the anti-metastasis efficacy.

2021-11-03 | GSE171230 | GEO

EpiChip: Gene-by-gene quantification of epigenetic modification levels

Project description:Using datasets for the H3KAc histone modification in Th2 cells and an accompanying IgG control, we present an analysis strategy termed 'EpiChip' that alternates between single gene and global data distribution levels and allows a clear distinction between experimental background and signal. Examination of H3KAc histone modifications in one cell type plus an IgG control.

2010-12-07 | E-GEOD-23092 | biostudies-arrayexpress

Nrf2 drives hepatocellular carcinoma progression through acetyl-CoA-mediated metabolic, epigenetic and oncogenic regulatory networks

Project description:Liver tumors had high levels of histone acetylation. Nrf2 knockout mice developed fewer tumors than Nrf2 wild-type mice. The mechanistic study found that Nrf2 knockout reduced the generation of acetyl CoA from impaired glycolysis, TCA cycle, and fatty acid metabolism. Acetyl CoA is the substrate for protein acetylation including histone acetylation. Here we determined the genome-wide distribution of AcH3K27. We found that Nrf2 through regulating acetyl CoA production affects histone acetylation (AcH3K27) to modulate the expression of genes, whose products were involved in the glycolysis, TCA cycle, fatty acid metabolism, and oncogenic Myc/mTor signaling. Our findings supported an Nrf2-integrated metabolic, epigenetic and oncogenic signaling in driving liver tumor development.

2023-03-20 | GSE227068 | GEO

PD-1 restrains glycolysis for histone acetylation to suppress T-cell lymphoma

Project description:PDCD1, which encodes for the PD-1 immune checkpoint receptor, is a key tumor suppressor in T cells that is recurrently inactivated in human T cell non-Hodgkin lymphomas (T-NHLs)1-3. The highest frequencies of PDCD1 deletions are detected in advanced disease, predicting inferior prognosis2. Nevertheless, the tumor-suppressive mechanisms of PD-1 signaling remain unknown. Using tractable mouse models of human T-NHL, we demonstrate that PD-1 activity in pre-malignant cells prevents cellular transformation by inhibiting the induction of rate-limiting factors for glucose uptake and conversion upon oncogenic T cell signaling. Furthermore, PD-1 negatively regulates ATP-citrate lyase (ACLY), which generates extramitochondrial acetyl-CoA for histone acetylation. Consequently, inactivation of PD-1 enables oncogene-expressing T cells to switch to glycolysis to metabolically fuel overt malignancy and unleashes ACLY activity to promote de novo histone acetylation to increase chromatin accessibility of oncogenic AP-1 transcription factors. Multimodal molecular and functional analyses of primary human T-NHL samples confirmed enforced glucose metabolism, epigenetic reprogramming, and AP-1 activation upon PDCD1 loss in patients. Thus, our results identified PD-1 as a central metabolic gatekeeper of T cell transformation and lymphoma progression and established a mechanistic link between the PD-1 checkpoint receptor and glucose-dependent histone acetylation. Together, these data uncover novel putative genotype-specific vulnerabilities in T-NHL and present a starting point for the exploration of PD-1 dependent epigenetic reprogramming in T cell biology.

2023-08-09 | GSE183530 | GEO

The histone acetylation reader ENL is required for oncogenic transcription driven by super-enhancer and represents a synergistic vulnerability for BET inhibition [RNA-seq]

Project description:The histone acetylation reader ENL is identifed as a key factor controlling super-enhancer-driven transcription. Therefore, we constructed a targeted degradation system of endogenous ENL protein and investigated the roles of ENL in regulating oncogenic transcription through epigenetic reprogramming.

2024-01-18 | GSE230421 | GEO

The histone acetylation reader ENL is required for oncogenic transcription driven by super-enhancer and represents a synergistic vulnerability for BET inhibition [ChIP-seq]

2024-01-18 | GSE230420 | GEO

The histone acetylation reader ENL is required for oncogenic transcription driven by super-enhancer and represents a synergistic vulnerability for BET inhibition [ChIP-Seq II]

2024-01-18 | GSE249553 | GEO

Glioma proteome - Quantitative proteomics reveals fundamental regulatory differences in oncogenic HRAS and IDH1 driven astrocytoma

Project description:In the present study, we applied a quantitative MS-based strategy to characterize the proteome and phosphoproteome in HRAS- or IDH1-driven glioma cells. We describe the driving roles of the MEK and PI3K signaling pathways in RAS-NHA cells, and uncover oncogenic signaling in other pathways. We highlight the interplay between the signaling cascades and show that inhibition of MEK and PI3K reverses phosphorylation signaling patterns driven by oncogenic RAS overexpression. Applying a histone hybrid chemical labeling method and high-resolution MS, we identified significant histone methylation, acetylation, and butyrylation changes in IDH1mut-NHA cells. Our results suggest a global transcriptional repressive state, consistent with the down-regulation of the proteome, transcriptome, and the DNA hyper-methylated state in IDH1mut-NHA cells. We provide a unique resource of altered proteins, phosphosites, and histone PTMs in RAS and IDH1 mutant astrocytoma cell lines, providing insight into oncogenesis in glioma beyond the transcriptomic level.

2016-12-23 | PXD004945 | Pride

Interplay between H2A.Z and epigenome in PANC-1

Project description:The oncogenic process is regulated by a complex network of different regulatory elements in charge of regulate the cancer epigenome. The histone variant H2A.Z is involved in the regulation of different regulatory elements such as promoters and enhancers in different types of cancer, however, the interplay between the H2A.Z and the cancer epigenome is poorly understood. Here, we investigate the functional role of H2A.Z at promoters, enhancers, super enhancers and topologically associating domains in the pancreatic cancer cell line PANC-1. We found an oncogenic role of H2A.Z regulated by acetylation and deacetylation as well as the potential interactions with epigenetic regulators such as EZH2 and CTCF. Specifically, we found that the presence of H2A.Z facilitates the recruitment of RNA polymerase II and other transcription factors such as ZNF384 at promoters, enhancers and super enhancers, allowing the gene expression. On the other hand, the absence of acetylation is associated with an enrichment of EZH2 allowing transcriptional repression of transcription factors associated with cancer development. Also, we identified that H2A.Z is a component of the TAD boundaries in PANC-1, and its enrichment is associated with the presence of transcription factors such as CTCF, ZNF143 and ZNF384. Together, these data show new mechanisms associated with the interplay between H2A.Z and the epigenome in pancreatic cancer.

2021-04-15 | GSE172050 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data